Invert has filed a notice of an exempt offering of securities to raise $20,100,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Invert is raising up to $20,100,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Martin Permin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Invert
Invert builds software for bioprocessing. With Invert, your team has full transparency into all your bioprocess data from lab to production, including full process traceability from upstream to formulation. Your team will save time juggling manual data, get to insights faster, and collaborate seamlessly across teams and partners. Made for biopharma, synthetic biology, and CDMOs.
To learn more about Invert, visit http://www.invertbio.com/
Invert Linkedin Page: https://www.linkedin.com/company/invertinc/
Contact:
Martin Permin, Chief Executive Officer
415-798-0792
https://www.linkedin.com/in/permin/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.